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Objectives: Because neural invasion (NI) is still inconsistently reported and
not well characterized within gastrointestinal malignancies (GIMs), our aim
was to determine the exact prevalence and severity of NI and to elucidate the
true impact of NI on patient’s prognosis.
Background: The union internationale contre le cancer (UICC) recently
added NI as a novel parameter in the current TNM classification. However,
there are only a few existing studies with specific focus on NI, so that the
distinct role of NI in GIMs is still uncertain.
Materials and Methods: NI was characterized in approximately 16,000
hematoxylin and eosin tissue sections from 2050 patients with adenocarci-
noma of the esophagogastric junction (AEG)-I-III, squamous cell carcinoma
(SCC) of the esophagus, gastric cancer (GC), colon cancer (CC), rectal cancer
(RC), cholangiocellular cancer (CCC), hepatocellular cancer (HCC), and pan-
creatic cancer (PC). NI prevalence and severity was determined and related to
patient’s prognosis and survival.
Results: NI prevalence largely varied between HCC/6%, CC/28%, RC/34%,
AEG-I/36% and AEG-II/36%, SCC/37%, GC/38%, CCC/58%, and AEG-
III/65% to PC/100%. NI severity score was uppermost in PC (24.9 ± 1.9)
and lowest in AEG-I (0.8 ± 0.3). Multivariable analyses including age, sex,
TNM stage, and grading revealed that the prevalence of NI was significantly
associated with diminished survival in AEG-II/III, GC, and RC. However,
increasing NI severity impaired survival in AEG-II/III and PC only.
Conclusions: NI prevalence and NI severity strongly vary within GIMs. De-
termination of NI severity in GIMs is a more precise tool than solely recording
the presence of NI and revealed dismal prognostic impact on patients with
AEG-II/III and PC. Evidently, NI is not a concomitant side feature in GIMs
and, therefore, deserves special attention for improved patient stratification
and individualized therapy after surgery.
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G astrointestinal malignancies GIMs are the second leading causeof cancer-related deaths, with an utmost bad prognosis, espe-
cially in pancreatic cancer (PC).1 The most effective and promising
chance for curative treatment in nearly all GIMs is neoadjuvant treat-
ment, followed by resection or resection by adjuvant treatment. Cur-
rently, decision whether or not to give neoadjuvant/adjuvant therapy is
mostly dependent on the TNM classification. Therefore, clinical and
histopathological analysis is inevitable to avoid undertreatment and
improve survival. Here, easy and accessible novel prognostic tools
beyond the TNM classification may be helpful to attain better pa-
tient’s stratification and thus more individualized and efficient cancer
therapy. Neural invasion (NI) might represent such a novel tool.
Presently, in head/neck and prostate tumors, NI is recognized
as an important route of cancer spread, and its presence has high
impact on treatment.2,3 Since the potential impact of NI has been rec-
ognized, the UICC has recently added NI as a novel parameter in the
current TNM classification.4 The incorporation of NI into the TNM
classification was an important step, but until today, we do not exactly
know what kind of additional information we gain and furthermore,
how or whether we should react and change our therapy regimes
according to the stage of NI. However, current literature on the exis-
tence of NI in GIM is confusing. There exists a great variability of
NI prevalence rates not only between different GIMs but also even
within 1 tumor entity. For example, in colorectal cancer, NI is present
with a prevalence rate of 6% to 26%, in gastric cancer (GC) widely
ranging between 2% and 76%, and in PC between 45% and 98%.5–10
These great discrepancies are due to unfocused studies, divergent NI
definitions, and especially due to lack of a common definition for NI
in GIMs. Thus, the importance of a uniform characterization of NI
within GIMs is urging, and the characterization of its true impact on
patient prognosis within GIM is mandatory.
Therefore, in the present study, we aimed to establish a com-
prehensive and reliable characterization of NI and thereby assessing
its true prevalence in GIMs. Furthermore, a robust NI severity score
system was used to define the impact of NI on survival and prognosis
within GIMs.
MATERIALS AND METHODS
Patient and Specimen Selection
In the present study, adenocarcinomas of the esophageal junc-
tion (AEG)-I-III, squamous cell carcinomas (SCCs) of the esopha-
gus, GC, colon cancer (CC), rectal cancers (RCs), cholangiocellular
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cancers (CCCs), hepatocellular cancer (HCC) and PCs were included.
In order not to distort the original state of NI with any kind of neoad-
juvant therapy, patients with neoadjuvant therapy, additional malig-
nancies, and emergency operations were excluded from the study.
Thus, a total of 2050 patients with GIMs were consecutively selected
between January 1987 and June 2009 at our institution (Table 1).
The median age was 65 ± 11.6 years. Informed consent for tissue
collection was obtained before surgery. Adjuvant therapy was initi-
ated in 5% (3/58) in AEG-II, 3% (2/65) in AEG-III, 3% (6/184) in
GC, 19% (19/114) in CCC, 6% (3/47) in HCC, 100% (132/132) in
PC, 36% (385/1075) in CC, and 41% (77/187) in RC. Patients with
AEG-I and SCC did not receive any kind of adjuvant therapy. To
mimic daily routine pathological work, all hematoxylin and eosin–
stained sections from regular pathologic examination were used to
perform the comprehensive histopathological reevaluation. Accord-
ing to previous publications, at least 3 primary tumor slides and all
slides showing lymph nodes and their surrounding tissue were used to
classify and characterize NI.11,12 On average, 8 tissue sections were
analyzed for NI prevalence and severity in each patient with a total of
approximately 16,000 sections. Histopathological analysis was per-
formed by 3 independent observers (F.L., K.M., and J.G.D.) blinded
to patient survival data, followed by resolution of any differences by
joint review and consultation with third observers (K.B., R.L., and
F.B.), as reported before.11–13
Definition and Establishment of a Novel NI Severity
Score in GIMs
NI severity score was determined for all GIMs, as recently
shown.11–13 Three NI stages were determined: (i) epineural tumor
associations (ENA), lesions in which cancer cells directly touch the
epineural sheet without penetrating the perineurium (Fig. 1A); (ii)
perineural invasion (PNI), defined as cancer cells within the per-
ineurium (Fig. 1B); and (iii) endoneural invasion (ENI), as infiltra-
tion of cancer cells into the endoneurium (Fig. 1C). The presence of
cancer cells inside the ganglionic capsules of the Auerbach plexus
or the direct contact with the myenteric plexus cells was separately
noted as invasion to Auerbach plexus (Fig. 1D).
All nerves in the entire tissue specimens were categorized and
scored as non–cancer-invaded (0), ENA (1), PNI (2), or ENI (3).
Individual NI severity score was generated by adding the number
of invaded nerves (n) with the respective NI category, as shown in
the following formula: Individual NI severity score = n(ENA) × 1
+ n(PNI) × 2 + n(ENI) × 3, as recently shown.11,12 The final NI
severity score of each individual patient was calculated by the mean
of the 3 different scores of the 3 independent observers.
Statistical Analysis
The χ 2 test was used for comparisons of frequency data be-
tween independent patient groups. The Mann-Whitney U test was
conducted to compare level of semiquantitative data between 2 un-
related samples. Survival distribution was estimated and illustrated
according to Kaplan-Meier method. The log-rank test was applied
to assess survival differences between independent groups. Cox re-
gression analysis was used for multivariable analysis, and resulting
estimates of hazard ratios (HRs) were provided with 95% confidence
intervals (CIs). Based on the fitted Cox regression models, predicted
survival probability curves for 6, 12, 24, and 48 months were calcu-
lated and displayed in dependence on the observed NI severity score
levels. Following general recommendations on regression modeling
strategies, we considered well-established prognostic factors as ad-
justment variables in the multivariable analysis.14 These variables
included age, pathologic tumor stage, tumor grading, metastasis sta-
tus, nodal status, and sex. For 2 reasons, we did not consider P
value–based selection of potential confounder variables: first, due to
the large sample size of the study data set, even clinically irrelevant
factor-outcome associations would reveal small P values. Second,
it has been shown that associational criteria are neither necessary
nor sufficient to demonstrate presence or absence of confounding.15
Interrater reliability regarding the NI severity score assessment was
evaluated by the intraclass correlation coefficient (ICC). All tests were
2-sided, and a P value of less than 0.05 was considered to indicate
statistical significance. No correction of P values was conducted to
correct for multiple test issues.16
RESULTS
Prevalence of NI Varies Within GIMs
In the upper gastrointestinal tract, NI was present in 36% of
patients with AEG-I, in 36% of patients with AEG-II, in 65% of
patients with AEG-III, in 37% of patients with SCC, and in 38% of
patients with GC. In the lower gastrointestinal tract, 28% of patients
with CC and 34% of patients with RC exhibited NI. Patients with
hepatobiliary cancer revealed NI in 6% of patients with HCC and in
58% of patients with CCC. Impressively, in PC, all patients presented
NI (100%; Table 1).
The prevalence rates of Auerbach plexus were 29% in AEG-I,
28% in AEG-II, 29% in AEG-III, 14% in SCC and in GC and CC,
and finally 12% in RC.
PC Has the Highest NI Severity Among All GIMs
Interrater reliability regarding the NI severity score assessment
was evaluated by the intraclass correlation coefficient and revealed
TABLE 1. Patient Characteristics









± SD 1 2 3 4 0 1 2 3 0 1 1 2 3 4
AEG I 96 36 94:6 65 ± 11.6 44 32 24 0 55 39 6 0 96 4 4 41 54 1
AEG II 58 36 76:24 66 ± 11.9 17 55 23 5 31 43 10 16 85 15 3 29 64 4
AEG III 65 65 66:34 72 ± 13.2 8 48 35 9 28 23 23 26 74 26 2 19 74 5
SCC esophagus 92 37 78:22 55 ± 9.1 36 26 34 4 46 53 1 0 86 14 1 34 61 4
Gastric cancer 184 38 55:45 67 ± 12.7 32 35 39 4 48 23 16 13 80 20 2 24 70 4
Colon cancer 1075 28 57:43 66 ± 11.6 10 13 53 24 56 21 23 — 75 25 3 59 37 1
Rectal cancer 187 34 63:37 62 ± 10.9 14 20 47 19 56 23 21 — 91 9 1 70 29 0
CCC 114 58 49:51 64 ± 10.3 10 37 44 9 48 42 10 0 97 3 3 44 50 3
HCC 47 6 68:32 61 ± 9.3 23 30 45 2 30∗ 0 — — 100 0 7 59 32 2
Pancreatic cancer 132 100 59:41 64 ± 9.6 2 4 90 4 16 84 — — 89 11 2 57 41 0†
∗Only 14 patients had resected lymph nodes, all without infiltration of tumor cells.
†Missing data for grading of 23 patients.
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FIGURE 1. Definition of NI on representative hematoxylin and eosin–stained tissue sections: A, Epineural association: Cancer cells
directly touch the epineurium but not penetrate it. B, Perineural invasion: Cancer cells are within the perineural sheet. The tumor
cells directly touch and displace the nerve but are not destroying its bundle integrity. C, Endoneural invasion: Arrow shows cancer
cells within the endoneural structures. They have invaded through the perineurium into the endoneural sheet. D, Representative
hematoxylin and eosin–stained picture of cancer cell invasion into Auerbach plexus. The arrow shows normal myenteric plexus
ganglia between both muscular layers. Magnifications are shown in the right lower corner of the images. E, Neural invasion
severity score values for each tumor entity presented in mean ± standard error of the mean. Note significant smaller values for
malignancies of the upper and lower gastrointestinal tract in comparison with pancreatic cancer. ∗indicates a significant difference
P < 0.05 compared to pancreatic cancer/PC.
excellent agreement between the 3 raters (intraclass correlation co-
efficient = 0.991; 95% CI, 0.990–0.992). Significant differences in
NI severity were present between GIMs (P < 0.001; Fig. 1E). The
lowest NI severity score was detected in AEG-I: 0.8 ± 0.3 (mean ±
SEM), followed by CC: 2.1 ± 0.2, RC: 2.9 ± 0.2, SCC: 3.1 ± 0.8,
GC: 3.9 ± 0.7, and HCC: 5.1 ± 2.3. Medium level NI severity scores
were detected in AEG-II: 6.3 ± 1.6 and AEG-III: 6.3 ± 1.1, followed
by patients with CCC: 12.0 ± 2.0. The highest NI severity score of
all GIMs was recorded in PC (24.9 ± 1.9).
Prevalence of NI and Impact on Survival
The median follow-up period of all 2050 patients was 37
months (interquartile range: 12.8–78.0). To attain a valid survival
analysis, AEG-II and AEG-III were united to 1 group (AEG-II/III)
because of their similar cancer biology and close location. The over-
all 5-year survival (5y-OS) for AEG-I was 40 ± 6.7%. In patients
with AEG-I with NI, 5y-OS was 28 ± 9% compared with 49 ± 9%
without NI (P value log-rank test = 0.038; Fig. 2A). In patients with
AEG-II/III, 5y-OS was 36 ± 5%, which was significantly impaired
Copyright © 2014 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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FIGURE 2. Graphs depict Kaplan-Meier analysis of survival depending on occurrence of NI for each tumor entity Upper gastroin-
testinal tumor including A, AEG I; B, AEGII/III; C, SCC; D, Gastric cancer/GC; E, Cholangiocellular cancer/CCC; F, hepatocellular
cancer/HCC; G, colon cancer; H, rectal cancer. With the exception of HCC, patients’ survival was significantly impaired when NI
was detected in every tumor entity.
in patients with NI (20 ± 6%) compared with patients without NI
(45 ± 8%; P < 0.001; Fig. 2A). Patients with SCC had a 5y-OS
of 43 ± 9%. A significant difference was found in patients with NI
positive versus NI negative SCC (27 ± 11% vs 59 ± 12%; P = 0.024,
Fig. 2A). Patients with GC demonstrated a 5y-OS of 46 ± 4%, with a
significant longer 5y-OS in patients without NI than in patients with
NI (64 ± 5% and 21 ± 6%; P < 0.001; Fig. 2A).
In patients with HCC, the 5y-OS was 59 ± 8%, with no
difference in 5y-OS between patients with or without NI (33 ± 27%
vs 61 ± 8%; P = 0.121, Fig. 2B). 5y-OS in patients with CCC was
28 ± 5%, with a significant difference between patients without NI
(43% ± 8%) compared with patients with NI (18 ± 5%, P = 0.009;
Fig. 2C). 5y-OS of patients with PC was the lowest with 19 ± 3%.
Because all patients with PC demonstrated NI, no subanalysis (NI
positive vs NI negative) was performed.
In the lower gastrointestinal tract, 5y-OS for CC and RC was
69 ± 2% and 70 ± 4%, respectively. Patients with CC and RC without
NI (77 ± 2% and 88 ± 3%) demonstrated a significantly better 5y-
OS than patients with NI (48 ± 3% and 34 ± 6%, P < 0.001;
Figs. 2D, E).
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A noteworthy number of patients receiving adjuvant therapy
were registered only in CC (36%), RC (41%), and CCC (19%), be-
sides PC (100%). To test whether adjuvant therapy had an impact
on overall survival within patients with CC, RC, and CCC, a multi-
variable analysis including NI (yes/no), sex, age, TNM, grading, and
adjuvant therapy was performed. It was evident that only in CC (HR,
0.60; 95% CI, 0.45–0.79; P < 0.001; see Supplemental Digital Con-
tent Table 1, available at http://links.lww.com/SLA/A641) adjuvant
therapy was identified as an independent prognostic factor, whereas
in RC and CCC, this was not the case. To test the potential impact of
adjuvant therapy in patients with NI positive CC, we performed an
additional multivariable analysis including sex, age, TNM, grading,
and adjuvant therapy. It was obvious that in this special subset of
patients with NI, adjuvant therapy lost its function as an indepen-
dent prognostic factor, demonstrating that adjuvant treatment of CC
(HR, 0.69; 95% CI, 0.45–1.04; P = 0.075; see Supplemental Digital
Content Table 1, available at http://links.lww.com/SLA/A641) had no
distinct impact on survival in patients with NI.
Prognostic Potential of NI Prevalence and Severity
in GIMs
To determine the prognostic quality of NI, 2 separate multi-
variate analyses were performed: (1) the simple presence of NI as
covariate or (2) more accurate, the NI severity score, as it allows
a more individualized analysis of NI. Because all patients with PC
feature NI, prognostic analysis was performed only with the NI sever-
ity score. Cox regression analysis included also common prognostic
factors such as sex, age, pTNM status, and tumor grading.
Within the multivariate analyses, the sole presence of NI did
not show any prognostic power in AEG-I-III, SCC, CCC, HCC, and
CC (Table 2). Only in GC and RC, the sole presence of NI signifi-
cantly diminished patients’ survival. In GC, the likelihood of dying
among NI present patients was almost doubled (HR, 1.73; 95% CI,
1.10–2.73; P < 0.02), and in RC, the probability of dying was even
3 times higher in patients with NI (HR, 3.01; 95% CI, 1.59–5.67;
P = 0.001; Table 3). Cox regression analysis, using NI severity as a
covariate, demonstrated no independent prognostic power, neither in
AEG-I and SCC nor in GC (Table 3). However, NI in AEG-II/III was
an independent prognostic factor (HR, 1.16; 95% CI, 1.02–1.30; P <
0.02; Table 3). In patients with CCC, HCC, CC, and RC, NI sever-
ity showed no independent prognostic potential. However, in PC, NI
severity was identified as an additional independent prognostic factor
(HR, 1.09; 95% CI, 1.04–1.15, P < 0.001; Table 3).
Escalating NI Severity Scores Bear Diminished
Survival
A regression model estimated the survival probabilities de-
pendent on NI severity scores. This model revealed a firm illustration
of the estimated association of higher NI severity levels and poorer
survival in patients with AEG-II/III, HCC, colorectal cancer, and PC
(Figs. 3A–E). For example, patients with AEG-II/III with a severity
score of 20 points had a 40% chance to survive 12 months post-
operatively. In contrast, if the NI severity score was 40, 12-month
survival probability was only 10% (Fig. 3A). Although NI prevalence
in HCC was the lowest among all GIMs, patients with HCC exhibited
particularly impaired survival with increasing NI severity. When the
NI severity score rose from 2 to 4, estimated survival probability was
remarkably reduced by almost 50% (70% vs 34%; Fig. 3B). Although
NI is not a frequently observed phenomenon in patients with HCC,
it was evident that once NI was detected, these affected patients had
an utmost bad prognosis with a more than 2-fold higher risk of dying
and even a more than 7-fold higher risk of dying with increasing NI
severity scores (Fig. 3B and Tables 2 and 3). Similarly, patients with
PC with an NI score of 20 points had a 60% likelihood of surviving
12 months postoperatively. However, if the NI severity score was 40,
estimated survival was decreased by more than 50% (Fig. 3D).
DISCUSSION
The present study provides the largest and most comprehensive
currently available analysis on NI in more than 2000 patients with
10 different cancers of the gastrointestinal tract. It demonstrates in
a standardized manner that the prevalence of NI and tumor-specific
TABLE 2. Multivariable Analysis NI
AEG I AEG II + III SCC Esophagus Gastric Cancer
Variable HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
NI presence (yes vs no) 1.01 0.38–2.68 0.977 1.63 0.97–2.75 0.064 1.51 0.21–11.0 0.687 1.73 1.10–2.73 0.018
Female vs male 1.27 0.27–6.04 0.762 1.03 0.61–1.76 0.897 0.63 0.18–2.14 0.455 0.93 0.61–1.42 0.745
Age 0.98 0.94–1.01 0.207 1.03 1.01–1.05 0.012 0.98 0.92–1.03 0.399 1.04 1.02–1.06 <0.001
pT 3/4 vs 1/2 1.58 0.63–3.97 0.331 2.04 1.14–3.62 0.016 1.63 0.28–9.57 0.589 1.50 0.89–2.52 0.131
pN
1 vs 0 2.89 1.29–6.46 0.010 3.64 1.48–8.93 0.005 1.51 0.21–11.0 0.687 2.47 1.33–4.56 0.004
2 vs 0 3.68 1.00–13.5 0.50 5.00 1.84–13.6 0.002 1.24 0.35–2.45 0.489 4.16 2.13–8.12 <0.001
3 vs 0 — — — 7.60 2.83–20.4 <0.001 — — — 3.54 1.61–7.77 0.002
pM1 vs pM0 1.35 0.23–3.44 0.974 1.79 0.94–3.41 0.78 2.13 0.63–7.29 0.226 3.29 1.75–6.17 <0.001
G 3/4 vs 1/2 1.47 0.66–3.28 0.351 1.19 0.60–2.34 0.619 0.66 0.28–1.58 0.352 0.74 0.42–1.30 0.297
HCC CCC Colon Cancer Rectal Cancer
Variable HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
NI presence (yes vs no) 2.10 0.43–10.1 0.357 1.64 0.95–1.82 0.077 1.06 0.83–1.34 0.664 3.01 1.59–5.67 0.001
Female vs male 0.59 0.18–1.95 0.390 0.88 0.55–1.43 0.613 1.25 1.00–1.56 0.055 0.70 0.41–1.20 0.194
Age 1.00 0.96–1.06 0.871 1.03 1.01–1.06 0.012 1.01 1.00–1.02 0.065 1.01 0.99–1.04 0.278
pT 3/4 vs 1/2 1.77 0.63–4.93 0.276 2.54 1.50–4.30 0.001 2.85 1.60–5.09 <0.001 2.26 0.92–5.55 0.074
pN
1 vs 0 — — — 2.96 1.75–5.00 <0.001 2.73 1.93–3.86 <0.001 1.23 0.59–2.56 0.575
2 vs 0 — — — 2.07 0.88–4.90 0.098 4.90 3.44–6.97 <0.001 3.30 1.65–6.63 0.001
pM1 vs pM0 — — — 2.57 0.81–8.17 0.110 5.47 4.19–7.15 <0.001 4.71 2.26–9.82 <0.001
G 3/4 vs 1/2 2.60 1.03–6.52 0.042 1.72 1.04–2.86 0.035 1.27 1.01–1.61 0.042 2.01 1.17–3.47 0.012
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TABLE 3. Multivariable Analysis NI Severity Score
AEG I AEG II + III SCC Esophagus Gastric Cancer Pancreatic Cancer
Variable HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
NI severity score∗ 0.99 0.67–1.44 0.940 1.16 1.02–1.30 0.019 0.97 0.78–1.19 0.733 1.04 0.94–1.15 0.485 1.09 1.04–1.15 <0.001
Female vs male 1.51 0.32–7.23 0.606 1.13 0.66–1.95 0.657 0.68 0.21–2.22 0.521 1.01 0.67–1.54 0.962 0.92 0.62–1.34 0.656
Age 0.98 0.94–1.01 0.211 1.03 1.01–1.05 0.009 0.98 0.92–1.03 0.387 1.04 1.02–1.06 <0.001 1.03 1.01–1.04 0.008
pT 3/4 vs 1/2 1.40 0.66–3.03 0.389 2.08 1.16–3.74 0.014 2.43 0.81–7.28 0.112 1.62 0.97–2.71 0.065 0.87 0.38–2.02 0.753
pN
1 vs 0 2.48 1.13–5.43 0.023 3.54 1.43–8.76 0.006 2.10 0.82–5.40 0.123 2.68 1.45–4.96 0.002 1.47 0.87–2.49 0.151
2 vs 0 3.33 1.04–10.7 0.043 5.31 1.91–14.7 0.001 1.20 0.76–2.33 0.274 4.37 2.23–8.56 <0.001 — — —
3 vs 0 — — — 9.44 3.55–25.1 <0.001 — — — 4.06 1.85–8.92 <0.001 — — —
pM1 vs pM0 0.81 0.72–2.34 0.648 1.58 0.84–2.95 0.155 3.00 0.83–10.9 0.095 3.53 1.87–6.66 <0.001 1.32 0.75–2.34 0.343
G 3/4 vs 1/2 1.84 0.83–4.07 0.940 1.31 0.66–2.60 0.442 0.66 0.27–1.61 0.361 0.77 0.43–1.35 0.356 1.73 1.13–2.65 0.011
CCC HCC Colon Cancer Rectal Cancer
Variable HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
NI severity score∗ 1.04 0.98–1.10 0.187 7.52 0.90–62.8 0.063 1.00 0.94–1.07 0.916 1.03 0.95–1.11 0.500
Female vs male 0.91 0.56–1.48 0.708 0.60 0.18–1.99 0.407 1.25 1.00–1.57 0.048 0.67 0.39–1.17 0.159
Age 1.03 1.01–1.05 0.017 1.00 0.95–1.05 0.969 1.01 1.00–1.02 0.060 1.02 1.00–1.04 0.114
pT 3/4 vs 1/2 2.67 1.60–4.45 <0.001 1.68 0.60–4.68 0.325 2.87 1.61–5.12 <0.001 3.88 1.70–8.86 0.001
pN
1 vs 0 3.00 1.78–5.06 <0.001 — — — 2.74 1.93–3.87 <0.001 1.47 0.73–2.96 0.279
2 vs 0 1.97 0.82–4.75 0.132 — — — 5.00 3.52–7.11 <0.001 5.02 2.57–9.81 <0.001
pM1 vs pM0 2.26 0.73–6.95 0.156 — — — 5.58 4.27–7.29 <0.001 3.72 1.81–7.64 <0.001
G 3/4 vs 1/2 1.65 0.98–1.10 0.047 2.47 0.98–6.23 0.056 1.28 1.01–1.62 0.042 1.90 1.11–3.25 0.020
∗The corresponding hazard ratio values display the estimated risk increment associated with a NI severity score gain of 5 points.
NI severity and their impact on prognosis differ extensively between
GIMs and confirm PC as the most neuroaffine gastrointestinal cancer
entity.
The biological impact of NI was first recognized in prostate and
head/neck cancers and was followed in the past years by intensifying
research in PC.3,13,17–19 Research of NI in GIMs is limited, and there is
a noticeable discrepancy in the definition and analysis of NI.10,17,20–25
This inconsistency resulted in highly variable NI prevalence rates
even in studies on the same tumor entity. Moreover, most NI data
were retrospectively extracted from routine pathology reports rather
than targeted reexamination of tissue specimens, which is known to
yield more precise prevalence rates.25
To determine the true prevalence and impact of NI in GIMs, all
patients with neoadjuvant therapy regimens were excluded because
of the well-known influence of neoadjuvant therapy on prevalence
and severity of NI in patients with AEG and RC.11,26,27 By using
a standardized definition, a very wide range of prevalence rates for
NI in GIMs from 6% in HCC up to 100% in PC could be detected.
There may be several reasons for this remarkable difference: First,
the natural anatomic density of peripheral nerves in visceral organs
is different. This may explain the very low prevalence of NI in HCC,
because the liver is distant to major nerve plexus (ie, celiac and hy-
pogastric plexus) as opposed to the pancreas, which is—in addition to
possessing a large amount of autonomic nerves—also located in the
immediate neighborhood of the celiac plexus. This anatomical dif-
ference may also account for the nearly 10-fold higher NI prevalence
of 58% in extrahepatic CCC and of 65% in AEG-III with greater
proximity to the celiac plexus. However, nerve density may not be the
only reason for this discrepancy, because in RC with its dense rectal
neural plexus, NI prevalence reaches a mere 34% when compared
with 100% for PC.28,29 Nevertheless, PC is the most aggressive neu-
roinvasive tumor among all GIMs, because regardless of tumor stage,
there was not a single patient in whom NI was absent.
In recent studies, we demonstrated that cancer cells of different
origin exhibit varying extents of neuroaffinity, as best seen in the 3-
dimensional neural-migration assay.12,18,30 In such an in vitro setting,
PC cells demonstrate an evidently faster and more targeted migration
toward nerves as opposed to CC and RC cells.12 Furthermore, it is
known that neuroplastic changes actively support the generation of NI
in PC, but not all GIM subtypes are able to induce these neuroplastic
alterations.12,13,31 In PC, neuroplastic alterations like increased neu-
ral density and hypertrophy are induced by potent neurotropic factors
such as nerve growth factor and Artemin.11,13,19 In CC, the amount
of nerve growth factor and Artemin in colonic nerves are much less
than in pancreatic nerves in PC. Furthermore, CC cells as opposed
to PC cells are not capable of inducing neuroplastic alterations in
cultured neurons. Therefore, it seems that the observed noticeable
differences in NI prevalence between the GIMs may be due to dif-
ferent neurotropic attributes of each cancer cell type with distinct
neurocancer affinities. In this context, it is of importance that not
only the frequency of NI was different within the GIMs but also their
aggressiveness to invade nerves, as seen in the noticeable different NI
severity scores. It was evident that the more destructive the NI behav-
ior was, the more impaired prognosis was detected in the majority of
all GIMs. Here again, PC showed the most aggressive NI phenotype
with the highest NI severity scores (24.9), whereas patients with CC
revealed only very low scores (2.9).
Apart from PC, AEG-II/III turned out to be the only other GIM
where NI severity had a noticeable impact on survival. Only little in-
formation is available on the presence of NI and its impact on survival
in AEG, because NI was not well defined and not the main focus of
the analysis.20,26,27 However, these limited data corroborate our data
by indicating that patients with AEG-II and -III reveal higher preva-
lences of NI than patients with AEG-I, that NI was identified as an
independent prognostic factor in patients with AEG and GC, and that
neoadjuvantly treated patients with AEG seem to exhibit significantly
reduced NI.20,26,27 Whether AEG tumors also feature neurotropic at-
tributes as known in PC must be investigated in future studies.
Now the important question remains whether this novel knowl-
edge has any clinical consequence. Because all patients with PC
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FIGURE 3. Estimated survival probability (y axis) for 6, 12, 24, and 60 months according to the NI severity score (x axis)
Upper gastrointestinal tumor including A, AEG I; B, AEGII/III; C, SCC; D, Gastric cancer/GC; E, Cholangiocellular cancer/CCC; F,
pancreatic cancer; G, colorectal cancer; H, hepatocellular cancer. Note the strikingly diminished predicted survival with increasing
NI severity scores. Arrow lines and dotted arrow lines exemplify increasing NI severity score and its corresponding estimated
survival probability. Dash bars at the x axis depict actually observed severity score levels of all patients in each cancer entity.
receive adjuvant chemotherapy, one can discuss whether patient with
a primarily resectable PC with a distinct NI severity score can be
upgraded and categorized as a patient with a locally advanced cancer.
To improve the efficacy of such an adjuvant regime in this special
patient population with a defined NI severity cutoff value, physicians
may consider more aggressive adjuvant therapy options including
chemotherapy (eg, FOLFIRINOX) and/or radiochemotherapy.32
Similarly, patients with CC with T3–T4 N0 (stage II) tumors do
normally not receive any adjuvant chemotherapy.33 However, one
may consider adjuvant therapy for these patients if they demonstrate
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extraordinarily high NI severity scores. These novel data raise a lot
of important questions that have to be taken seriously. The first step
must be the identification of the different NI severity cutoff scores
via prospective controlled studies.
Advances in systematic histopathological assessment and
molecular cancer phenotyping allowed identification of leading prog-
nostic factors in GIMs. Between the UICC stages I to III, lympho-
vascular invasion significantly shortens the 5y-OS of patients with
esophageal cancer, GC, or CC.34 Similarly, microsatellite instability
is encountered in 15% of sporadic CC and GC and is increasingly
recognized to identify a subpopulation of patients with a favorable
prognosis.35,36 Patients with metastatic CC and mutated BRAF gene
have a mere 10.4-month overall survival time when compared with
34.7 among BRAF wild-type patients.37 Therefore, a major future ob-
jective shall be to identify the prognostic significance of NI in relation
to established prognostic factors in GIMs.
CONCLUSIONS
Our present data clearly demonstrate that NI is not a concomi-
tant side feature in GIMs and deserves special attention due to its
prognostic and potential therapeutic impact. Therefore, implemen-
tation of a standardized routine-based analysis of NI prevalence in
combination with the individual NI severity score may enable us now
to react and improve patient stratification and individualized thera-
peutic decision making after surgery.
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DISCUSSANTS
M. Krawczyk (Warsaw, Poland):
First of all, I would like to thank the authors for the permission
to read the article and would also like to thank the European Surgical
Association for the privilege of being the first discussant of this
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interesting study. In the article, the authors present a large cohort of
2050 patients with adenocarcinoma of the esophago-gastric-junction,
squamous cell carcinoma of the esophagus, gastric cancer, colon and
rectal cancer, cholangiocellular, hepatocellular cancer (HCC), and
pancreatic cancer. The aim of the study was to determine whether the
neural invasion differentiated in various GIM tumors, and the clinical
impact, if any, of this.
I have 1 remark regarding the material. The authors excluded
patients who had undergone neoadjuvant therapy from the analysis.
However, they did not exclude patients who had received adjuvant
therapy. Such a difference may have had an influence on the results
and overall survival.
Moreover, I have 2 other remarks.
It is true that the authors have found the answer to the aim
of their study, as in pancreatic cancer and in adenocarcinomas of the
esophageal-junction/AEG II/III NI-severity was significant. These re-
sults are comparable with those supplied by the authors of the TNM
classification. Nevertheless, paying attention to the neural invasion
in pancreatic cancer and adenocarcinoma of the esophago-gastric-
junction is of academic significance because it is known that the
prognosis for both cancers is very poor. Thus, the outcome of pan-
creatic cancer and adenocarcinoma of the esophago-gastric-junction
highlights only the problem.
However, it is much more difficult to analyze the clinical impact
and, particularly, determine whether the outcome of NI invasion can
help us to individualize treatments after surgery. To accomplish this
task, it is necessary that we analyze a comparable number of patients
in each group. For example, in the HCC group, you studied only 47
cases, whereas in the colon cancer group, you analyzed 1075 cases.
We require a prospective study.
Response From G.O. Ceyhan, H. Friess (Munich,
Germany):
Thank you very much for your comments and excellent ques-
tions. First of all, we excluded all patients treated with neoadjuvant
therapy from the analysis because we did not want to distort the nat-
ural biology of neural invasion in our patients. We wanted to be sure
that this is the clear-cut picture of neural invasion within our patient
population. Concerning our data obtained from patients with rectal
cancer and other patients, especially patients with AEG, we know
that neoadjuvant treatment reduces the prevalence of neural invasion.
To answer the question of whether adjuvant treatment had an effect
on our results, we analyzed this important aspect in our entire study
population. Most of the patients did not receive adjuvant treatment.
For instance, none of the patients with AEG I and a squamous cell
carcinoma of the esophagus received adjuvant therapy. Only 3% of
the patients with AEG II/III and gastric cancer and up to 6% of those
with HCC received adjuvant therapy.
Furthermore, 36% of patients with colon cancer, 41% of pa-
tients with rectal cancer, and 19% of patients with cholangiocellular
carcinoma received adjuvant treatment. We performed a multivari-
able analysis, including neural invasion, and identified only adjuvant
therapy as an independent prognostic factor in patients with colon
cancer. Moreover, we performed another subanalysis of the patients
with colon cancer with the presence of neural invasion and investi-
gated whether adjuvant therapy had an impact, finding that this was
not the case. Therefore, adjuvant therapy seems to not have had an
impact on our results. All patients with pancreatic cancer received
adjuvant therapy. To exclude pancreatic cancer from the study, due
to its 100% penetrance of adjuvant regimens, would be excluding the
golden control group, in which we know that neural invasion has a
major impact on survival.
Regarding your second remark, you’re completely right. Pa-
tients with AEG and pancreatic cancer have a poor prognosis. We
face the following problem in our daily practice in patients with pan-
creatic cancer, where we operate these patients who have advanced
tumor disease; they are resected and intraoperative frozen sections
are used to identify neural invasion. What is the consequence of this
important information? In short, nothing; we completed the opera-
tion and the patient received adjuvant therapy. Seven months later,
the patient came back with back pain; a computed tomographic scan
is obtained and the local recurrence is identified, typically at the su-
perior mesenteric artery and/or at the coeliac plexus, indicating local
recurrence due to the neural invasion of cancer cells. To avoid this
in the future, we have to identify patients who have a high risk of
developing early local recurrence. One possible way to do this is to
generate a clear defined neural invasion severity cutoff and with this
information, identify patients with an advanced case of the disease
and offer them a more aggressive adjuvant therapy regimen.
With regard to your third question, I completely agree with you.
At the moment, there’s a prospective study running at our department,
in which we want to identify the cutoff value for neural invasion
severity in pancreatic cancer.
DISCUSSANTS
N. Senninger (Mu¨nster, Germany):
I just have a brief comment. I think that it would be worthwhile
to pursue the whole thing with native specimens because then you can
better examine the inflammatory potential surrounding this invasive
process. My question is the following: did you measure inflammatory
cells in these tumors, such as tumor-invading lymphocytes, to get a
feeling of what the mechanism is that propels the cells into the nerves?
Perhaps it is not the metastatic potential but rather, inflammatory side
effects.
Response From G.O. Ceyhan, H. Friess (Munich,
Germany):
This is also a very interesting question and we have also worked
on this subject. We have recently published our findings in Plos One.
We reported that the more perineural inflammatory cell infiltrations
were present around the intrapancreatic nerves, the more aggressive
the neural invasion of cancer cells observed was. This means that the
inflammatory cell infiltration runs in parallel with neural cancer cell
invasion and is somehow augmenting it. A more detailed analysis of
this issue is still undergoing.
DISCUSSANTS
J. Reynolds (Dublin, Ireland):
I enjoyed your article. I just have two questions. First, lympho-
vascular invasion is often paralleled with perineural invasion. Was
this evaluated in your multivariate analysis? Second, some people
think Siewert type 2 tumors have a gastric origin, whereas others
argue that they are esophageal. Are we to read anything in the close
parallel between type 2 and type 3 tumors from your study data?
Response From G.O. Ceyhan, H. Friess (Munich,
Germany):
With regard to the first question, because we did not have data
on lymphovascular invasion in all patients, we had to exclude this
object from our study.
In answer to your second question, due to the limitations of
our study, we found that AEG II and III behave similarly regarding
neural invasion and were clearly different from patients with AEG I
and other esophageal cancer. Therefore, this observation supports the
theory that Siewert type 2 tumors behave more like gastric cancer.
However, this hypothesis needs more investigation.
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